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NSAID UTILIZATION AMONG COMMERCIALLY 
INSURED MEMBERS IN A MANAGED 
CARE ENVIRONMENT
Hall J, Clouse J,
Ingenix International, Eden Prairie, MN, USA
OBJECTIVE: To evaluate nonsteroidal anti-inflamma-
tory drug (NSAID) utilization among commercially in-
sured members in a managed care environment. METH-
ODS: This was a cross-sectional study of administrative
pharmacy claims data from eleven health plans between
July 1, 1994 and June 30, 1997. Data were used to deter-
mine the prevalence of prescription NSAID use. Analyses
were performed on two groups: those with and those
without a rheumatoid arthritis or osteoarthritis diagnosis
occurring 90 days prior to their first NSAID claim dur-
ing the study period. Members were required to be con-
tinuously enrolled with a drug benefit during the study
period (N  149,216). Acute NSAID utilization (defined
as 3 prescriptions during the study period), chronic
NSAID utilization (defined as 3 NSAID prescriptions
during the study period), and average day supply were
analyzed. RESULTS: The prevalence of NSAID use
among continuously enrolled health plan members of all
ages was 32% during the three-year study period. Among
members with arthritis, 37% were considered acute
NSAID users and 63% were considered chronic users. A
30 to 34 days supply of NSAIDs was most common for
members with arthritis. Among members without arthri-
tis, 71% were considered acute NSAID users and 29%
were considered chronic users. A 10 to 15 day supply
was most common for members without a recent arthritis
diagnosis. CONCLUSION: The majority of NSAID users
in the managed care population used NSAIDs on an
acute basis. Consequently, use of the more costly, new
class of NSAIDS, COX-2 inhibitors, which may reduce
the incidence of gastrointestinal (GI) bleeding among
those at increased risk of GI irritation due to chronic
NSAID exposure, may not be warranted for most NSAID
users.
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Health related quality of life (HQL) measures provide
benchmarks by which to judge the effectiveness of treat-
ment that might otherwise be lost by relying on labora-
tory measures. OBJECTIVE: To compare the impact of 3
treatments for early RA (3 years) on HQL. METH-
ODS: The SF-36 Health Survey (SF-36) and the Health
Assessment Questionnaire (HAQ) were self-administered
by 632 patients participating in a double-blind, random-
ized, controlled clinical trial of three treatments (etaner-
cept 25 mg and 10 mg and methotrexate) for early RA.
Patients were followed over the course of one year with 9
interim follow-up assessments. RESULTS: Treatment
had its greatest impact on measures of physical health
status, specifically the SF-36 physical (PCS) and HAQ
summary scales. To a lesser degree treatment also im-
proved mental health status as determined by the SF-36
mental (MCS) summary scale. Patients in the etanercept
25 mg and MTX groups improved by as much as a stan-
dard deviation on both PCS (10 points) and HAQ (1 point)
summary scales by week 52. Patients in the etanercept 10
mg group improved by nearly a standard deviation on
the HAQ (0.8 points) summary scale but only 1/2 of a
standard deviation on the PCS (5 points) scale by week
52. Average improvements in PCS and HAQ scores during
early follow-up (2- and 4-week) assessments for patients
receiving etanercept 25 mg were more than two times the
amount observed for patients receiving MTX (P 
0.001). CONCLUSION: A higher dose of Etanercept
achieved a quicker improvement of functioning and well
being that was maintained over the course of the year.
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IN PATIENTS WITH 
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of Pharmacy, University of Arizona, Tucson, AZ, USA; 3School 
of Medicine, University of Arizona, Tucson, AZ, USA
OBJECTIVES: The purpose of this study was to evaluate
the association between self-rating of physical and men-
tal health and changes in prescription therapy in the
course of the office visit in the treatment of patients with
musculoskeletal disorders. METHODS: Patients visiting
one of the two outpatient clinics in Tucson, Arizona with
arthritic symptoms as their chief complaint were invited
to complete a self-administered questionnaire. In addi-
tion to demographics and diagnoses information, data
was collected on medication profile, scores on a func-
tional status instrument (Health Assessment Question-
naire), and quality of life instruments (Feeling Thermom-
eter; 12-item Short Form Health Survey). The data were
collected between March and May 1998. RESULTS:
Among 772 patients, 112 (14.5%) received additional
medication following the visit, 29 (3.8%) had a medica-
tion discontinued, and 51 (6.6%) experienced both an
addition and a discontinuation of medication. According
to univariate statistics, patients who received additional
medication reported more functional limitation (P 
0.05) and poorer overall health (SF-12 Physical, P 
0.001; SF-12 Mental, P  0.005; FT, P  0.05), com-
pared to patients whose therapy remained unchanged.
After adjusting for age, gender, comorbid condition, spe-
